ISSN: 0167-6997

Journal Home

Journal Guideline

Investigational New Drugs Q1 Unclaimed

Kluwer Academic Publishers Netherlands

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Investigational New Drugs is a journal indexed in SJR in Pharmacology and Oncology with an H index of 97. It has a price of 3190 €. It has an SJR impact factor of 1,086 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,086.

Investigational New Drugs focuses its scope in these topics and keywords: acid, activity, solid, phase, growth, patients, study, cytotoxic, inhibits, tumor, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Pharmacology (Q1) Pharmacology (medical) (Q1) Pharmacology (medical) (Q1) Oncology (Q2)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,086

SJR Impact factor

97

H Index

95

Total Docs (Last Year)

516

Total Docs (3 years)

2870

Total Refs

1599

Total Cites (3 years)

511

Citable Docs (3 years)

2.92

Cites/Doc (2 years)

30.21

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1
Journal for ImmunoTherapy of Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

The Antiangiogenic Agent Neovastat (beta-941) Stimulates Tissue Plasminogen Activator Activity

A Novel Combination of Cisplatin, Irinotecan, and Capecitabine in Patients with Advanced Cancer

Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study

Treatment of AIDS Related Non-Hodgkin's Lymphoma with Combination Mitoguazone Dihydrochloride and Low Dose Chop Chemotherapy: Results of a Phase II study

The New Isothiocyanate 4-(Methylthio)Butylisothiocyanate Selectively Affects Cell-Cycle Progression and Apoptosis Induction of Human Leukemia Cells

A Phase I Trial of Daily Oral 4 -N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer

Emodin induced necroptosis in the glioma cell line U251 via the TNF-a/RIP1/RIP3 pathway

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors

Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand

SHOW MORE ARTICLES

Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma

Inhibition of Cell Growth, Induction of Apoptosis and Mechanism of Action of the Novel Platinum Compound cis-Diaminechloro-[2-(Diethylamino) Ethyl 4-Amino-Benzoate, N4]-Chloride Platinum (II) Monohydrochloride Monohydrate

Phase II Study of Interferon Gamma in Malignant Carcinoid Tumors (E9292): A Trial of the Eastern Cooperative Oncology Group

Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma

Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

Pharmacokinetic Drug-Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol